about
Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory scienceSystems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional MutagenesisPrediction of chemical-protein interactions network with weighted network-based inference methodPrediction of drug-target interactions and drug repositioning via network-based inferenceA Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer TypesSuppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCKComputational prediction of microRNA networks incorporating environmental toxicity and disease etiology.Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactomeQuantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapyMachine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic propertiesFunctional consequences of somatic mutations in cancer using protein pocket-based prioritization approach.FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach.SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents.Regulation rewiring analysis reveals mutual regulation between STAT1 and miR-155-5p in tumor immunosurveillance in seven major cancers.Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approachA cross-cancer differential co-expression network reveals microRNA-regulated oncogenic functional modulesccmGDB: a database for cancer cell metabolism genesSystematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based ApproachHeterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer.Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomesSystematic dissection of dysregulated transcription factor-miRNA feed-forward loops across tumor types.Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs.Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes.Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.In silico ADMET prediction: recent advances, current challenges and future trends.Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.In silico polypharmacology of natural products.Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.Entropy-based Consensus Clustering for Patient Stratification.Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer.In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method.SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning.Drug Repurposing: New Treatments for Zika Virus Infection?Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties.Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.Pharmacophore modeling of human adenosine receptor A(₂A) antagonists.Estimation of ADME properties with substructure pattern recognition.Classification of cytochrome P450 inhibitors and noninhibitors using combined classifiers.
P50
Q26778374-24F1500B-C7A1-4751-AF4B-08558ED8DA40Q27468694-EF923AC3-E211-41AE-8B9A-5C41609F5630Q28481329-D8A63282-F4FA-4BAB-8269-AEC199798FC4Q28483634-E44BEFCF-07A7-42B7-B9F9-B0DE11F7FF88Q28547803-032C87ED-3B98-4C96-89B9-F82F14FC0FC7Q28833740-3BA4E90A-E257-4B08-9B7A-4B3B6C1276AEQ33846279-E8953CE3-77D6-4692-AE8E-52DA769BBE79Q33923533-EB52F135-7B85-40D6-948E-6611A0A17E88Q33977022-318B7534-43B4-48C3-BFB8-AE2C60E65B79Q34235803-DC7CCB63-7DF8-41DC-B739-7C0AF62D26F0Q34423170-B636E0C3-6BEE-4091-9CFE-2241F319F1CCQ35025312-0C55F516-5142-4BE1-A474-A428C31F660BQ35593948-D6F13761-FF4E-4AC4-A340-29F6958BA4D5Q35834269-8D38EC14-A6BE-4BF8-9993-6DAE3F7EAF70Q36120373-5D97870B-0554-408A-9404-1894AB80D81CQ36275831-9F492BDC-94E3-4666-BD17-7D76C8AF586FQ36434684-910E8515-15B6-4B1F-ACB7-A4C762CEFC82Q36539506-EA780B22-2514-4D6F-A1B6-50F9C90AAA45Q36672248-D34A9FB8-D0A2-4E6C-9AD9-87EC8B1B2C8CQ37096363-134FF0EB-8186-415C-96AA-1B3420D5C559Q37480571-65AFEC79-72A7-4558-BC2E-5B6F155D4209Q37564492-55A8A06E-8772-4CBB-BB82-A90E6067E89AQ37575496-6C08B175-3B19-4D2D-83F8-2D8ABEE5ADC4Q37708902-2E34A64F-C5B8-480C-9EDA-EA55C9373E9FQ38107020-70ED86B7-EA34-434A-BD35-E11E2EB76767Q38379632-6EED5C64-B05E-4583-85C6-B7764CE2BF75Q38381789-5C029E2D-325E-48A0-9B59-D617C2FB2C58Q38810969-1C25B00D-EF78-4C25-98EF-D44507EE1557Q38843575-DF00A3DE-D84E-4D3B-B985-F79EBA7C33C3Q38860341-273E8248-AB01-4EB6-A913-A1C4B7E6BAC3Q39257898-A4F34B88-1CFD-4759-9301-CD3A10BAC0DAQ39523695-01408402-CFBA-484D-A68E-15B9576F3B0DQ39947451-1D7D0353-D5B5-408B-B84A-A449FD5CCF96Q40054261-BA8FA3C7-EF35-4994-90B9-9873A0A2428AQ41459790-9BE08A6E-FD52-411D-8A3B-BF10F31932D4Q42673952-765542C7-0050-49F2-8943-630287CD2A86Q43033518-384EF843-AEE6-482A-B018-F5859AB8A54DQ43132147-3C087F7C-C8AE-4E6E-A989-5DD8281DB2A5Q43821108-F5A5560A-15F2-402F-B92F-7A504E6773A0Q44560804-85D17BDE-44FE-44AC-B955-8B9F52C55FDF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Feixiong Cheng
@ast
Feixiong Cheng
@en
Feixiong Cheng
@es
Feixiong Cheng
@fr
Feixiong Cheng
@nl
Feixiong Cheng
@sl
type
label
Feixiong Cheng
@ast
Feixiong Cheng
@en
Feixiong Cheng
@es
Feixiong Cheng
@fr
Feixiong Cheng
@nl
Feixiong Cheng
@sl
prefLabel
Feixiong Cheng
@ast
Feixiong Cheng
@en
Feixiong Cheng
@es
Feixiong Cheng
@fr
Feixiong Cheng
@nl
Feixiong Cheng
@sl
P106
P108
P2038
Feixiong_Cheng3
P21
P31
P496
0000-0002-1736-2847